{"id":305042,"date":"2026-02-19T00:00:00","date_gmt":"2026-02-19T00:00:00","guid":{"rendered":"http:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfop0002-2024-biopharma-diabetic-macular-edema-diabetic-retinopathy-landscape-forecast-disease-2\/"},"modified":"2026-03-31T10:23:27","modified_gmt":"2026-03-31T10:23:27","slug":"dlsfop0002-2026-biopharma-diabetic-macular-edema-diabetic-retinopathy-landscape-forecast-disease-landscape-forecast","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfop0002-2026-biopharma-diabetic-macular-edema-diabetic-retinopathy-landscape-forecast-disease-landscape-forecast\/","title":{"rendered":"Diabetic Macular Edema \/ Diabetic Retinopathy &#8211; Landscape &#038; Forecast &#8211; Disease Landscape &#038; Forecast (G7)"},"content":{"rendered":"<p>Diabetic macular edema (<abbr title=\"diabetic macular edema\">DME<\/abbr>), a complication of diabetic retinopathy (<abbr title=\"diabetic retinopathy\">DR<\/abbr>), develops as a result of persistently elevated blood sugar levels and can lead to vision loss or blindness if left untreated. The treatment landscape for <abbr title=\"diabetic retinopathy\">DR<\/abbr> and <abbr title=\"diabetic macular edema\">DME<\/abbr> is evolving rapidly, with established anti-<abbr title=\"vascular endothelial growth factor\">VEGF<\/abbr> therapies such as Eylea, Lucentis, and off-label Avastin remaining central to management. Additionally, the sustained-release corticosteroid implants Ozurdex and Iluvien provide alternative options. Since 2022, the market has seen increased competition with the launch of Vabysmo, Eylea HD, and Pavblu, the first biosimilar of Eylea. The anticipated approvals of Regenxbio \/ AbbVie\u2019s sura-vec <abbr title=\"suprachoroidal space\">SCS<\/abbr> and 4DMT \/ Otsuka\u2019s 4D-150\u2014two innovative gene therapies\u2014and EyePoint\u2019s Duravyu, Ocular Therapeutix\u2019s Axpaxli, and Ashvattha\u2019s migaldendranib\u2014three novel <abbr title=\"tyrosine kinase inhibitor\">TKI<\/abbr>s\u2014represent a breakthrough in the treatment of retinal diseases. Moreover, non-intravitreal therapies<a> <\/a>such\u00a0as Oculis\u2019s OCS-01, a topical eye drop formulation, are likely to shift the current treatment paradigm and could transform the treatment of <abbr title=\"diabetic macular edema\">DME<\/abbr> patients in the future.\u00a0<\/p>\n<p><strong>Questions answered<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>How large are the treatable <abbr title=\"diabetic retinopathy\">DR<\/abbr> and <abbr title=\"diabetic macular edema\">DME<\/abbr> populations, and how will diagnosis and drug-treatment rates change over time?<\/li>\n<li>What key differences do <abbr title=\"key opinion leader\">KOL<\/abbr>s perceive between current <abbr title=\"intravitreal\">IVT<\/abbr> therapies? How is the use of these drugs expected to change over the next 10 years?<\/li>\n<li>How will <abbr title=\"diabetic retinopathy\">DR<\/abbr> and <abbr title=\"diabetic macular edema\">DME<\/abbr> treatment algorithms change as innovative products like gene therapies and long-acting <abbr data-abbreviation-entity=\"4974\" title=\"tyrosine kinase inhibitor\">TKI<\/abbr>s launch?<\/li>\n<li>How will market dynamics be impacted by the launch of biosimilars of Eylea?<\/li>\n<\/ul>\n<p><strong>Product description<\/strong><\/p>\n<p>Disease Landscape &#038; Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:<\/p>\n<ul class=\"round-bullets\">\n<li>Optimize your long-term disease and development strategy.<\/li>\n<li>Quantify market potential for your pipeline assets and those of your competitors.<\/li>\n<li>Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.<\/li>\n<li>Gauge the commercial outlook and impact of key market events.<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-305042","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-diabetic-macular-edema","biopharma-therapy-areas-diabetic-retinopathy","biopharma-therapy-areas-ophthalmology","biopharma-date-2609"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/305042","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":10,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/305042\/revisions"}],"predecessor-version":[{"id":575196,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/305042\/revisions\/575196"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=305042"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}